Literature DB >> 2294131

Evening versus morning injections of growth hormone (GH) in GH-deficient patients: effects on 24-hour patterns of circulating hormones and metabolites.

J O Jørgensen1, N Møller, T Lauritzen, K G Alberti, H Orskov, J S Christiansen.   

Abstract

Since serum GH in normal subjects displays a circadian variation with a major and consistent surge after the onset of sleep we examined whether the time of GH administration in GH-deficient patients had any impact on its action. Eight GH-deficient patients all underwent 3 4-week study schedules in random order: 1) evening (2000 h) sc GH injections, 2) morning (0800 h) sc GH injections, and 3) no GH administration. At the end of each period the patients were admitted to hospital for 24-h measurements of hormones and metabolites. For comparison, 10 age- and sex-matched healthy untreated subjects were hospitalized once under identical conditions. Mean (+/- SE) GH availability, i.e. the area under the curve (AUC; micrograms per L/12 h) for 12 h after injection was significantly greater after evening injection than after morning injections [83.3 +/- 25.4 (evening) vs. 46.0 +/- 10.6 (morning); P less than 0.01]. This might be due to higher skin and sc temperatures when in bed. The 2000-0800 h AUC after evening injection was similar to the corresponding AUC in the reference group. Mean 24-h serum insulin-like growth factor-I levels (micrograms per L) were similar after evening (189.8 +/- 2) and morning (179.5 +/- 5.3) injections (P = 0.8), but the latter displayed a circadian variation suggesting that a steady state had not been reached. Both were significantly lower than the stable reference value (248.4 +/- 3.6 micrograms/L). Blood glucose profiles after morning and evening GH did not differ from that of the reference group, whereas blood glucose decreased when the patients received no GH (P less than 0.01). Daytime (0800-2400 h) insulin levels were increased after morning injections (P less than 0.05). Nighttime levels of lipid intermediates were below normal in the untreated state and after morning injection (P less than 0.05), whereas nighttime blood alanine tended to be above normal after morning GH injection (P = 0.08). Highly significant inverse relationships between circadian lipid intermediates and both blood alanine and lactate concentrations were observed in the reference group and in the patients after evening injections. These relationships disappeared after morning injections. We conclude that the metabolic effects of sc GH injections are clearly influenced by the time of administration and that the closest similarity to normal hormone and metabolite patterns and relationships is reached by GH injection in the evening in GH-deficient patients.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2294131     DOI: 10.1210/jcem-70-1-207

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  16 in total

1.  Long-term GH treatment of GH-deficient adults: comparison between one and two daily injections.

Authors:  C Höybye; M Rudling
Journal:  J Endocrinol Invest       Date:  2006-12       Impact factor: 4.256

2.  Long-acting growth hormone.

Authors:  Charlotte Höybye; Jens Sandahl Christiansen
Journal:  Paediatr Drugs       Date:  2013-12       Impact factor: 3.022

Review 3.  Growth hormone therapy for people with thalassaemia.

Authors:  Chin Fang Ngim; Nai Ming Lai; Janet Yh Hong; Shir Ley Tan; Amutha Ramadas; Premala Muthukumarasamy; Meow-Keong Thong
Journal:  Cochrane Database Syst Rev       Date:  2017-09-18

4.  Growth hormone therapy for people with thalassaemia.

Authors:  Chin Fang Ngim; Nai Ming Lai; Janet Yh Hong; Shir Ley Tan; Amutha Ramadas; Premala Muthukumarasamy; Meow-Keong Thong
Journal:  Cochrane Database Syst Rev       Date:  2020-05-28

5.  Managing idiopathic short stature: role of somatropin (rDNA origin) for injection.

Authors:  J Paul Frindik; Stephen F Kemp
Journal:  Biologics       Date:  2010-06-24

6.  Effects of exercise during normoxia and hypoxia on the growth hormone-insulin-like growth factor I axis.

Authors:  W Schmidt; S Doré; A Hilgendorf; S Strauch; R Gareau; G R Brisson
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1995

Review 7.  Effect of growth hormone on insulin signaling.

Authors:  Rita Sharma; John J Kopchick; Vishwajeet Puri; Vishva M Sharma
Journal:  Mol Cell Endocrinol       Date:  2020-09-20       Impact factor: 4.102

Review 8.  Development, production and pharmacodynamics of human growth hormone.

Authors:  J T Jørgensen; T Chirstensen; M Jørgensen; G Jakobsen
Journal:  Indian J Pediatr       Date:  1991 Sep-Oct       Impact factor: 1.967

9.  The Effects of 20-kDa Human Placental GH in Male and Female GH-deficient Mice: An Improved Human GH?

Authors:  Edward O List; Darlene E Berryman; Reetobrata Basu; Mathew Buchman; Kevin Funk; Prateek Kulkarni; Silvana Duran-Ortiz; Yanrong Qian; Elizabeth A Jensen; Jonathan A Young; Gozde Yildirim; Shoshana Yakar; John J Kopchick
Journal:  Endocrinology       Date:  2020-08-01       Impact factor: 4.736

Review 10.  Emerging options in growth hormone therapy: an update.

Authors:  Stephen F Kemp; J Paul Frindik
Journal:  Drug Des Devel Ther       Date:  2011-08-30       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.